Revolution Medicines Stock Intrinsic Value – Insiders Increase Holdings in Revolution Medicines, During the Past Year
July 8, 2023
☀️Trending News
Revolution Medicines ($NASDAQ:RVMD), Inc. is a biopharmaceutical company utilizing proprietary technologies to discover and develop novel, small molecule therapeutics to transform the treatment of cancer and other serious diseases. Over the past year, insiders at Revolution Medicines, Inc. have been net buyers of the company’s stock, with their holdings increasing during that time. This is evidenced by recently filed insider transactions with the Securities and Exchange Commission. This increased buying activity stands in stark contrast to the general bearish sentiment surrounding large-cap biopharmaceutical stocks over the past year.
The increasing insider purchases at Revolution Medicines could be an indication that the company’s executives are confident in the future prospects of the company and its products. It is worth noting that the buying activity has been spread across multiple insiders, indicating that the sentiment is shared by a broad range of individuals within the company.
Market Price
On Friday, Revolution Medicines, Inc. saw its stock open at $26.3 and close at $26.4, an increase of 0.7% from the prior closing price of $26.2. This rise in the stock’s price comes as insiders of the company have been steadily increasing their holdings in the past year. This increase in insider trading could be a sign that Revolution Medicines is headed for success in the near future.
The company also has a strategic collaboration with Merck & Co., Inc., under which Merck will be able to develop and commercialize certain product candidates arising from Revolution Medicines’ research collaboration with the Broad Institute of MIT and Harvard. Given the recent increase in insider holdings, investors seem optimistic about the future prospects of Revolution Medicines. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Revolution Medicines. More…
| Total Revenues | Net Income | Net Margin |
| 34.82 | -259.16 | -744.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Revolution Medicines. More…
| Operations | Investing | Financing |
| -231.63 | -64.14 | 625.33 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Revolution Medicines. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.07k | 121.03 | 8.96 |
Key Ratios Snapshot
Some of the financial key ratios for Revolution Medicines are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -10.4% | – | -765.0% |
| FCF Margin | ROE | ROA |
| -696.0% | -20.3% | -15.5% |
Analysis – Revolution Medicines Stock Intrinsic Value
GoodWhale’s financial analysis of REVOLUTION MEDICINES reveals that the fair value of the company’s share is approximately $20.7, as determined by our proprietary Valuation Line. Our data indicates that investors should be cautious when considering an investment in REVOLUTION MEDICINES at its current market price. More…
Peers
The company’s most advanced product candidate is RMC-4630, which is in development for the treatment of solid tumors. The company’s competitors include Rain Therapeutics Inc, Chinook Therapeutics Inc, and Erasca Inc.
– Rain Therapeutics Inc ($NASDAQ:RAIN)
Rain Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs to treat patients with cancer. The company’s lead product candidate is rivoceranib, a small molecule inhibitor of the tyrosine kinase receptor VEGFR2, which is in Phase III clinical trials for the treatment of second-line non-small cell lung cancer (NSCLC).
– Chinook Therapeutics Inc ($NASDAQ:KDNY)
Chinook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies for serious kidney diseases. The company’s lead product candidate, CHK-336, is a first-in-class, orally-administered small molecule inhibitor of the renal outer medullary potassium channel, or ROMK, which is being developed for the treatment of autosomal dominant polycystic kidney disease, or ADPKD. As of 2022, the company had a market cap of 1.38B and a return on equity of -11.14%.
– Erasca Inc ($NASDAQ:ERAS)
Erasca Inc is a biopharmaceutical company that focuses on the development of cancer therapies. The company has a market cap of 1.03B as of 2022 and a return on equity of -20.55%. Erasca’s focus on developing cancer therapies makes it a unique biopharmaceutical company, and its market cap and ROE reflect this. Erasca is a relatively new company, and its lack of profitability is to be expected. However, its focus on developing innovative cancer therapies gives it great potential for future growth.
Summary
Revolution Medicines, Inc. is a biopharmaceutical company focused on the discovery and development of new treatments for cancer and other diseases. An analysis of insider holdings in the company during the year shows that there has been net buying activity. This is usually interpreted as a sign of confidence in the future prospects of the company, and may be an attractive investment opportunity for potential investors. It is important for investors to do their own research and consult with a professional financial advisor before making any investment decisions.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
